195 related articles for article (PubMed ID: 34227689)
1. The safety of COVID-19 convalescent plasma donation: A multi-institutional donor hemovigilance study.
Cho JH; Rajbhandary S; van Buren NL; Fung MK; Al-Ghafry M; Fridey JL; Dy BA; Ziman A; Schreiber GB; Gammon RR; Reik R; Stubbs JR; van Buskirk CM; Kamel H; Townsend MJ; Zeller MP; Gottschall JL
Transfusion; 2021 Sep; 61(9):2668-2676. PubMed ID: 34227689
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 convalescent plasma donor characteristics, product disposition, and comparison with standard apheresis donors.
Lasky B; Goodhue Meyer E; Steele WR; Crowder LA; Young PP
Transfusion; 2021 May; 61(5):1471-1478. PubMed ID: 33458811
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of coronavirus disease 19 convalescent plasma donors and donations in the New York metropolitan area.
Jain S; Garg K; Tran SM; Rask IL; Tarczon M; Nandi V; Kessler DA; Strauss D; Sachais BS; Yazdanbakhsh K; Rehmani S; Luchsinger L; Shi PA
Transfusion; 2021 Aug; 61(8):2374-2383. PubMed ID: 33904609
[TBL] [Abstract][Full Text] [Related]
4. The safety of plasma apheresis from donors recovering from COVID-19 infection in Japan.
Kamo-Imai A; Togano T; Sato M; Kawakami Y; Inaba K; Shimazu H; Igarashi S; Tanaka K; Terada M; Kinoshita-Iwamoto N; Saito S; Kutsuna S; Hangaishi A; Morioka S; Takahashi K; Miyata S; Ohmagari N
Transfus Apher Sci; 2023 Jun; 62(3):103687. PubMed ID: 36964059
[TBL] [Abstract][Full Text] [Related]
5. Screening donors for COVID-19 convalescent plasma.
Wang HE; Ostrosky-Zeichner L; Katz J; Wanger A; Bai Y; Sridhar S; Patel B
Transfusion; 2021 Apr; 61(4):1047-1052. PubMed ID: 33368395
[TBL] [Abstract][Full Text] [Related]
6. How we secured a COVID-19 convalescent plasma procurement scheme in Japan.
Terada M; Kutsuna S; Togano T; Saito S; Kinoshita N; Shimanishi Y; Suzuki T; Miyazato Y; Inada M; Nakamoto T; Nomoto H; Ide S; Sato M; Maeda K; Matsunaga A; Satake M; Matsubayashi K; Tsuno H; Kojima M; Kuramistu M; Tezuka K; Ikebe E; Okuma K; Hamaguchi I; Shiratori K; Sato M; Kawakami Y; Inaba K; Igarashi S; Yamauchi R; Matsumura M; Ishimaru K; Zhang B; Kuge C; Ishihara M; Gouda M; Tanaka K; Ishizaka Y; Ohmagari N
Transfusion; 2021 Jul; 61(7):1998-2007. PubMed ID: 34096059
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of donor adverse reaction severity grading tool: enhancing objective grade assignment to donor adverse events.
Townsend M; Kamel H; Van Buren N; Wiersum-Osselton J; Rosa-Bray M; Gottschall J; Rajbhandary S
Transfusion; 2020 Jun; 60(6):1231-1242. PubMed ID: 32452048
[TBL] [Abstract][Full Text] [Related]
8. Demographics of first-time donors returning for donation during the pandemic: COVID-19 convalescent plasma versus standard blood product donors.
Van Buren NL; Rajbhandary S; Reynolds V; Gorlin JB; Stramer SL; Notari EP; Conti G; Katz L; Stubbs JR; van Buskirk CM; Kuttner K; Smith DL; Ngamsuntikul SG; Pandey S; Ward DC; Ziman A; Hiskey M; Townsend M; Sachais BS
Transfusion; 2023 Mar; 63(3):552-563. PubMed ID: 36550639
[TBL] [Abstract][Full Text] [Related]
9. Donors for SARS-CoV-2 Convalescent Plasma for a Controlled Clinical Trial: Donor Characteristics, Content and Time Course of SARS-CoV-2 Neutralizing Antibodies.
Körper S; Jahrsdörfer B; Corman VM; Pilch J; Wuchter P; Blasczyk R; Müller R; Tonn T; Bakchoul T; Schäfer R; Juhl D; Schwarz T; Gödecke N; Burkhardt T; Schmidt M; Appl T; Eichler H; Klüter H; Drosten C; Seifried E; Schrezenmeier H
Transfus Med Hemother; 2021 May; 48(3):137-147. PubMed ID: 34177417
[TBL] [Abstract][Full Text] [Related]
10. Donor tolerability of convalescent plasma donation.
He R; Lin H; Xie S; Lv Q; Kong Y; Li L; Xu H; Wang J; Li W; Fang P; Wu Y; Liu Z
J Clin Apher; 2021 Jun; 36(3):429-436. PubMed ID: 33587767
[TBL] [Abstract][Full Text] [Related]
11. Trends in return behavior after an adverse event in Australian whole blood and plasma donors.
Thijsen A; Masser B; Gemelli CN; Davison TE
Transfusion; 2019 Oct; 59(10):3157-3163. PubMed ID: 31403178
[TBL] [Abstract][Full Text] [Related]
12. The American Red Cross donor hemovigilance program: complications of blood donation reported in 2006.
Eder AF; Dy BA; Kennedy JM; Notari Iv EP; Strupp A; Wissel ME; Reddy R; Gibble J; Haimowitz MD; Newman BH; Chambers LA; Hillyer CD; Benjamin RJ
Transfusion; 2008 Sep; 48(9):1809-19. PubMed ID: 18631167
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 convalescent plasma donors: Unique motivations in unique times?
Crowder LA; Steele WR; Goodhue E; Lasky B; Young PP
Transfusion; 2023 Apr; 63(4):703-710. PubMed ID: 36866426
[TBL] [Abstract][Full Text] [Related]
14. Case-control study of immediate and delayed vasovagal reactions in blood donors.
Narbey D; Fillet AM; Jbilou S; Tiberghien P; Djoudi R
Vox Sang; 2016 Oct; 111(3):257-265. PubMed ID: 27232998
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for complications in donors at first and repeat whole blood donation: a cohort study with assessment of the impact on donor return.
Wiersum-Osselton JC; Marijt-van der Kreek T; Brand A; Veldhuizen I; van der Bom JG; de Kort W
Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s28-36. PubMed ID: 23867173
[TBL] [Abstract][Full Text] [Related]
16. Complications of blood donation reported to haemovigilance systems: analysis of eleven years of international surveillance.
Wiersum-Osselton JC; Politis C; Richardson C; Goto N; Grouzi E; Marano G; Land KJ
Vox Sang; 2021 Jul; 116(6):628-636. PubMed ID: 33278040
[TBL] [Abstract][Full Text] [Related]
17. Challenges in Establishing a Coronavirus Disease 2019 (COVID-19) Convalescent Plasma Donation Program in a Multicultural Environment.
Algora M; Mehmood T; Madison DL; AlAmeri J; Abuzakouk M; Tagamtam M; Acena L; Totaan G; Grabski G; Oumeziane N; Rajani P; Taylor L; Guzman J; AbdelWareth LO
Arch Pathol Lab Med; 2021 Dec; 145(12):1479-1484. PubMed ID: 34407176
[TBL] [Abstract][Full Text] [Related]
18. Adverse reactions to allogeneic whole blood donation by 16- and 17-year-olds.
Eder AF; Hillyer CD; Dy BA; Notari EP; Benjamin RJ
JAMA; 2008 May; 299(19):2279-86. PubMed ID: 18492969
[TBL] [Abstract][Full Text] [Related]
19. Deterrents in recruitment of COVID-19 convalescent plasma donors: Experience from a hospital-based blood centre in India.
Dhiman Y; Coshic P; Pandey HC; Khatiwada B; Singh J; Mehta V; Gupta S
Transfus Med; 2021 Jun; 31(3):149-154. PubMed ID: 33749020
[TBL] [Abstract][Full Text] [Related]
20. Limited window for donation of convalescent plasma with high live-virus neutralizing antibody titers for COVID-19 immunotherapy.
Gontu A; Srinivasan S; Salazar E; Nair MS; Nissly RH; Greenawalt D; Bird IM; Herzog CM; Ferrari MJ; Poojary I; Katani R; Lindner SE; Minns AM; Rossi R; Christensen PA; Castillo B; Chen J; Eagar TN; Yi X; Zhao P; Leveque C; Olsen RJ; Bernard DW; Gollihar J; Kuchipudi SV; Musser JM; Kapur V
Commun Biol; 2021 Feb; 4(1):267. PubMed ID: 33627795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
